Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Senti Biosciences, Inc. - Common Stock (NQ: SNTI )

0.3430 +0.0333 (+10.75%)
Streaming Delayed Price Updated: 3:23 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,340,900
Open 0.3275
Bid (Size) 0.3424 (150)
Ask (Size) 0.3500 (10)
Prev. Close 0.3097
Today's Range 0.3242 - 0.4380
52wk Range 0.2701 - 1.090
Shares Outstanding 2,752,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
From Senti Biosciences, Inc.
Via GlobeNewswire
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
SNTI stock results show that Senti Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-48.11%
-48.11%
1 Month
-8.07%
-8.07%
3 Month
-27.33%
-27.33%
6 Month
+22.06%
+22.06%
1 Year
-65.04%
-65.04%

More News

Read More
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Falls Sharply; Datadog Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Jumps 100 Points; US Trade Deficit Widens In September
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Mixed; D.R. Horton Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.